Download PDF
CC BY 4.0 · Indian J Med Paediatr Oncol
DOI: 10.1055/s-0044-1801738
Original Article

Pattern of Expression of PML-RARα Transcripts in Acute Promyelocytic Leukemia Patients and Its Correlation with Overall Survival: A Retrospective Study from Western India

Shweta Gondha
1   Department of Oncopathology, The Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India
,
Prerna Walia
1   Department of Oncopathology, The Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India
,
Beena Brahmbhatt
1   Department of Oncopathology, The Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India
,
Jayendrakumar Patel
2   Molecular Diagnostic and Research Lab, The Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India
,
Toral Mandalia
2   Molecular Diagnostic and Research Lab, The Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India
,
Disha Jethva
2   Molecular Diagnostic and Research Lab, The Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Introduction Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia with specific molecular pathogenesis, clinical features, and treatment. It is cytogenetically characterized by translocation t (15;17) (q24;q21). The location of breakpoints within the PML gene determines the formation of distinct promyelocytic leukemia-retinoic acid receptor α (PML-RARα) transcript subtypes which have prognostic significance. Breakpoints in intron 6 result in the long (L or bcr-1) subtype, those in exon 6 produce the variant (V or bcr-2) subtype, and breakpoints in intron 3 lead to the short (S or bcr-3) subtype.

Objectives The aim of our study was to determine the frequencies of the different PML-RARα transcripts in patients with APL at baseline and to investigate the impact of bcr-3 transcript as a prognostic factor on survival in newly diagnosed patients with APL.

Materials and Methods A retrospective study was conducted that included 54 newly diagnosed patients with APL. Clinicopathological parameters were evaluated in all cases for prognostic significance with overall survival. Real-time quantitative polymerase chain reaction was used for the quantification of PML-RARα transcripts.

Results Out of 54 patients, 53 (98.1%) patients expressed bcr-3 transcript either alone or in combination with either bcr-1 or bcr-2 transcripts. Twenty-one patients (38.9%) in our study showed expression of bcr-3 transcript only. Twenty eight (51.9%) patients in our study expressed all the three transcripts. Out of the 54 patients, 20 (37%) patients died of disease, out of which 19 patients died before completion of induction therapy. Complete remission was obtained in 34 patients (63%) after induction therapy. The survival rate for patients expressing the bcr-3 transcript alone was 66.66% as compared with 60.71% for patients expressing bcr-3 transcript in combination with other two transcripts. The survival rate for patients receiving all-trans retinoic acid (ATRA) in combination with arsenic trioxide was far better than patients receiving ATRA alone.

Conclusion The total leucocyte count is an independent prognostic factor in patients with APL as it was statistically significant with overall survival in our study. The bcr transcript either alone or in combination with bcr-1 and/or bcr-2 transcripts was the most frequent pattern observed.

Keywords

acute promyelocytic leukemia - PML-RARα transcripts - bcr-3 transcript


Publication History

Article published online:
05 February 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Liquori A, Ibañez M, Sargas C, Sanz MÁ, Barragán E, Cervera J. Acute promyelocytic leukemia: a constellation of molecular events around a single PML-RARA fusion gene. Cancers (Basel) 2020; 12 (03) 624-646
    CrossrefPubMedSearch in Google Scholar
  • 2 Iaccarino L, Divona M, Ottone T. et al. Identification and monitoring of atypical PML/RARA fusion transcripts in acute promyelocytic leukemia. Genes Chromosomes Cancer 2019; 58 (01) 60-65
    CrossrefPubMedSearch in Google Scholar
  • 3 Choppa PC, Gomez J, Vall HG, Owens M, Rappaport H, Lopategui JR. A novel method for the detection, quantitation, and breakpoint cluster region determination of t(15;17) fusion transcripts using a one-step real-time multiplex RT-PCR. Am J Clin Pathol 2003; 119 (01) 137-144
    CrossrefPubMedSearch in Google Scholar
  • 4 van Dongen JJ, Macintyre EA, Gabert JA. et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13 (12) 1901-1928
    CrossrefPubMedSearch in Google Scholar
  • 5 Gabert J, Beillard E, van der Velden VHJ. et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003; 17 (12) 2318-2357
    CrossrefPubMedSearch in Google Scholar
  • 6 Grimwade D, Jovanovic JV, Hills RK. et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 2009; 27 (22) 3650-3658
    CrossrefPubMedSearch in Google Scholar
  • 7 Yilmaz M, Kantarjian H, Ravandi F. Acute promyelocytic leukemia current treatment algorithms. Blood Cancer J 2021; 11 (06) 123
    CrossrefPubMedSearch in Google Scholar
  • 8 Testa U, Lo-Coco F. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients. Ann Hematol 2016; 95 (05) 673-680
    CrossrefPubMedSearch in Google Scholar
  • 9 Baba SM, Shah ZA, Pandith AA. et al. Influence of bcr-3 PML-RARα transcript on outcome in Acute Promyelocytic Leukemia patients of Kashmir treated with all-trans retinoic acid and/or arsenic tri-oxide. Cancer Genet 2019; 231–232: 14-21
    CrossrefPubMedSearch in Google Scholar
  • 10 Rasekh EO, Elsayed GM, Madney Y, El Gammal MM. Prognostic significance of bcr-1 and bcr-3 Isoforms of PML-RARA and FLT3-ITD in patients with acute promyelocytic leukemia. Clin Lymphoma Myeloma Leuk 2020; 20 (03) 156-167
    CrossrefPubMedSearch in Google Scholar
  • 11 Nath S, Bhattacharyya J, Chandra P, Saxena R, Sazawal S, Saikia KK. Clinicopathological significance of common genetic alterations in patients with acute promyelocytic leukemia. Hematol Oncol Stem Cell Ther 2022; 15 (02) 54-57
    CrossrefPubMedSearch in Google Scholar